Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma.

JNK (c-Jun N-terminal kinase) MUC1—mucin 1 TGF-beta non-canonical pathways pancreatic ductal adenocarcinoma

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2022
Historique:
received: 24 11 2021
accepted: 05 01 2022
entrez: 3 3 2022
pubmed: 4 3 2022
medline: 4 3 2022
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human cancers. Transforming Growth Factor Beta (TGF-β) is a cytokine that switches from a tumor-suppressor at early stages to a tumor promoter in the late stages of tumor development, by yet unknown mechanisms. Tumor associated MUC1 is aberrantly glycosylated and overexpressed in >80% of PDAs and is associated with poor prognosis. MUC1 expression is found in the early stages of PDA development with subsequent increase in later stages. Analysis of human PDA samples from TCGA database showed significant differences in gene expression and survival profiles between low and high MUC1 samples. Further, high MUC1 expression was found to positively correlate to TGF-βRII expression and negatively correlate to TGF-βRI expression in PDA cell lines. We hypothesized that MUC1 overexpression induces TGF-β mediated non-canonical signaling pathways which is known to be associated with poor prognosis. In this study, we report that MUC1 overexpression in PDA cells directly activates the JNK pathway in response to TGF-β, and leads to increased cell viability via up-regulation and stabilization of c-Myc. Conversely, in low MUC1 expressing PDA cells, TGF-β preserves its tumor-suppressive function and inhibits phosphorylation of JNK and stabilization of c-Myc. Knockdown of MUC1 in PDA cells also results in decreased phosphorylation of JNK and c-Myc in response to TGF-β treatment. Taken together, the results indicate that overexpression of MUC1 plays a significant role in switching the TGF-β function from a tumor-suppressor to a tumor promoter by directly activating JNK. Lastly, we report that high-MUC1 PDA tumors respond to TGF-β neutralizing antibody

Identifiants

pubmed: 35237602
doi: 10.3389/fcell.2022.821875
pii: 821875
pmc: PMC8883581
doi:

Types de publication

Journal Article

Langues

eng

Pagination

821875

Informations de copyright

Copyright © 2022 Bose, Grover, Sanders, Zhou, Ahmad, Shwartz, Lala, Nath, Yazdanifar, Brouwer and Mukherjee.

Déclaration de conflit d'intérêts

Author SN was employed by Wunderman Thompson Health IMsci. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Annu Rev Pathol. 2018 Jan 24;13:395-412
pubmed: 29414248
Trends Cancer. 2017 Jan;3(1):56-71
pubmed: 28718426
Mol Ther. 2021 Mar 3;29(3):920-936
pubmed: 33429081
Cancer Biol Ther. 2004 Nov;3(11):1081-9; discussion 1090-1
pubmed: 15467436
Semin Cell Dev Biol. 2016 Oct;58:96-107
pubmed: 27350026
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):E3785-94
pubmed: 25157176
Trends Cell Biol. 2006 Sep;16(9):467-76
pubmed: 16904320
Nat Rev Cancer. 2009 Dec;9(12):874-85
pubmed: 19935676
Cancers (Basel). 2021 May 03;13(9):
pubmed: 34063627
Comput Struct Biotechnol J. 2020 Sep 17;18:2568-2572
pubmed: 33005315
EMBO J. 2007 Sep 5;26(17):3957-67
pubmed: 17673906
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Science. 2002 May 31;296(5573):1646-7
pubmed: 12040180
Oncogene. 2012 Nov 22;31(47):4935-45
pubmed: 22266848
J Virol. 2012 Mar;86(6):3073-87
pubmed: 22238308
PLoS One. 2015 Feb 06;10(2):e0117097
pubmed: 25658419
Genes Dis. 2020 May 16;9(1):108-115
pubmed: 35005111
Pancreas. 2004 Apr;28(3):344-52
pubmed: 15084984
Cancer Res. 2002 Feb 1;62(3):910-6
pubmed: 11830551
Bioessays. 2001 Mar;23(3):223-32
pubmed: 11223879
EMBO J. 2000 Apr 17;19(8):1745-54
pubmed: 10775259
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
pubmed: 19723653
Cell. 1998 Dec 11;95(6):779-91
pubmed: 9865696
Int J Biochem Cell Biol. 2015 Feb;59:116-25
pubmed: 25526895
Int J Mol Sci. 2021 May 25;22(11):
pubmed: 34070449
Cell. 1996 Aug 23;86(4):543-52
pubmed: 8752209
PLoS One. 2014 Oct 24;9(10):e109695
pubmed: 25343336
J Clin Med. 2017 Nov 29;6(12):
pubmed: 29186029
Carcinogenesis. 2009 Feb;30(2):238-48
pubmed: 19056927
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cancer Res. 2011 Jul 1;71(13):4432-42
pubmed: 21558393
Trends Mol Med. 2014 Jun;20(6):332-42
pubmed: 24667139
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Oncotarget. 2018 Jan 5;9(6):6897-6910
pubmed: 29467938
Trends Mol Med. 2020 Mar;26(3):324-336
pubmed: 31753595
Dis Markers. 2017;2017:4934608
pubmed: 29138528
Oncogene. 2011 Mar 24;30(12):1449-59
pubmed: 21102519
Genes Dev. 2000 Mar 15;14(6):627-44
pubmed: 10733523
Future Oncol. 2021 Aug;17(23):3061-3076
pubmed: 34156282
Int J Biochem Cell Biol. 2008;40(3):383-408
pubmed: 18061509
Nature. 1994 Aug 4;370(6488):341-7
pubmed: 8047140
Cancer Cell Int. 2021 Jun 5;21(1):293
pubmed: 34090445
J Biol Chem. 2001 Apr 20;276(16):13057-64
pubmed: 11278868
Mol Cell Biol. 1994 Jun;14(6):3810-21
pubmed: 8196624
Cold Spring Harb Perspect Biol. 2016 Jul 01;8(7):
pubmed: 27328872
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Mol Cancer Res. 2006 Jul;4(7):489-97
pubmed: 16849524
Cell Res. 2009 Jan;19(1):128-39
pubmed: 19114990
Oncogene. 2016 Oct 27;35(43):5608-5618
pubmed: 26804176
J Cell Physiol. 2007 Dec;213(3):768-74
pubmed: 17516553
Oncogene. 2004 Jul 29;23(34):5858-63
pubmed: 15184869
J Immunol. 2008 Sep 1;181(5):3116-25
pubmed: 18713982
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Oncol Rep. 2014 Jul;32(1):189-98
pubmed: 24858567
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Curr Pharm Des. 2014;20(17):2934-47
pubmed: 23944366
PLoS One. 2010 Aug 19;5(8):e12243
pubmed: 20808857
Cancer Res. 2011 Feb 1;71(3):925-36
pubmed: 21266350
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207342
Nat Cell Biol. 2002 Dec;4(12):963-9
pubmed: 12447389
Medicine (Baltimore). 2019 Jan;98(1):e13820
pubmed: 30608394

Auteurs

Mukulika Bose (M)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Priyanka Grover (P)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Alexa J Sanders (AJ)

Department of Bioinformatics, UNC Charlotte, Charlotte, NC, United States.

Ru Zhou (R)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Mohammad Ahmad (M)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Sophia Shwartz (S)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Priyanka Lala (P)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Sritama Nath (S)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Mahboubeh Yazdanifar (M)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Cory Brouwer (C)

Department of Bioinformatics, UNC Charlotte, Charlotte, NC, United States.

Pinku Mukherjee (P)

Department of Biological Sciences, UNC Charlotte, Charlotte, NC, United States.

Classifications MeSH